Abstract
The desire to improve the therapeutic possibilities open to dermatologists in private practice and GPs has drawn attention increasingly to the problem of patient compliance. It therefore seemed advantageous to reduce both the number of daily applications necessary and the duration of treatment.
In a large number of mostly unicentre clinical trials bifonazole proved to be able to meet both these requirements for a modern antifungal agent.
In a high number of patients and in conditions usually found in dermatological practice, this multicentre study was aimed at demonstrating the qualities of bifonazole, in particular the possibilities of shorter treatment with consistently good efficacy and once-daily application.
During this study more than 6000 patients were treated with bifonazole. In approximately 90% of patients mycological and clinical cure were achieved; tolerance was good. The recommendation that the duration of treatment be reduced — to 2, 3 or 4 weeks, depending on the indications — was fully vindicated.
Bifonazole proved to be a preparation with properties contributing to patient compliance.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
References
Barug D, Bastiaanse HB (1983) An evaluation of the effect of bifonazole on Torulopsis glabrata and Candida albicans under various in vitro test conditions. Arzneim-Forsch/Drug Res 33: 524–528
Berg D, Regel E, Harenberg HE, Plempel M (1984) Bifonazole and clotrimazole. Their mode of action and the possible reason for the fungicidal behaviour of bifonazole. Arzneim-Forsch/Drug Res 34 (1): 139–146
Chu AC (1984) Comparative clinical trial of bifonazole solution versus selenium sulphide shampoo in the treatment of pityriasis versicolor. Dermatologica 169/S1: 81–86
Meinhof W (1984) Patient noncompliance in dermatomycosis. Results of a survey among dermatologists and general practioners and patients. Dermatologica 169/S1: 57–66
Patzschke K, Ritter W, Siefert HM, Weber H, Wegner LA (1983) Pharmacokinetic studies following systemic and tropical administration of (14C) bifonazole in man. Arzneim-Forsch/Drug Res 33 (1): 745–750
Plempel M, Büchel KH, Regel E (1982) Recent development in antifungal azole agents. Presented at VIII ISHAM Congress, Palmerstone North
Plempel M, Regel E (1982) Antimycotic properties of the topical azole bifonazole in vivo and in vitro. In Urabe H, Zaias N, Stettendorf S (eds) International antifungal symposium, Tokyo. Exerpta Medica 1982, pp 29–36
Plempel M, Regel E, Büchel KH (1983) Antimycotic efficacy of bifonazole in vitro and in vivo. Arzneim-Forsch/Drug Res 33 (1): 517–524
Reinel D (1984) Lokalbehandlung von Dermatomykosen mit Bifonazol. Med Welt 35: 182–184
Reinel D (1985) Die Lokalbehandlung der Pityriasis versicolor. Mykosen 28 (5): 225–231
Ritter W, Patzschke K (1984) Pharmakokinetik von Bifonazol. In: Meinhof W, Nolting S (eds) Bifonazol: Therapie von Dermatomykosen. Perimed, Erlangen, pp 29–34
Ritter W, Stettendorf S, Weber H (1982) Pharmacokinetics of bifonazole and their clinical implications. In: Urabe H, Zaias N, Stettendorf S (eds) International antifungal symposium, Tokyo. Exerpta Medica 1982, pp 48–59
Saffé F (1985) Bifonazol - Wirksamkeit und Verträglichkeit. In: Meinhof W, Nolting S (eds): Bifonazol: Therapie von Dermatomykosen. Perimed, Erlangen, pp 85–91
Shadomy S, Dixon DM, May R, Shadomy BL (1982): In vitro and in vivo activity of bifonazole. In: Urabe H, Zaias N, Stettendorf S (eds) International antifungal Symposium, Tokyo. Exerpta Medica 1982, pp 18–28
Stettendorf S (1983) Tolerability and efficacy of bifonazole in dermatomy-coses. Arzneim-Forsch/Drug Res 33 (1): 750–754
Stettendorf S (1984) Bifonazole - a synopsis of clinical trials worldwide. Status and outlook. Dermatologica 169/S1: 69–76
Szarmach H, Stettendorf S (1985) Klinische und mykologische Untersuchungen über die Wirksamkeit und Verträglichkeit von Bifonazol bei Hautmykosen. In: Meinhof W, Nolting S (1985) Bifonazol: Therapie von Dermatomykosen. Perimed, Erlangen, 39–46
Tessendorf R, Janssen K, Saffé F (1984) Dermatomykosen auf dem Vormarsch. Ärztl Praxis 36, (84): 2413–2414
Tessendorf R, Janssen K, Saffe F (1984) Neues Antimykotikum erhöht die Compliance. Ärztl Praxis 36, (99): 3049–3050
Tessendorf R, Janssen K, Saffe F (1985) Antimykotikum deckt breites Erregerspektrum ab. Ärztl Praxis 37 (10): 296–298
Voigt G (1985) Intertriginöse Mykosen und ihre Therapie. Ärztl Kos-metologie 15,178–183
Winter N, Winter G, Ulm K (1985) Bifonazol-überzeugendes Argument für lokale Behandlung der Tinea inguinalis. GIT Suppl 5 (5): 46–48
Zaias N, Battistini F, Gomez-Urcuyo F, Correa L, De la Rosa I (1982) Treatment of glabrous skin dermatophytosis with topical 1% bifonazole: a double-blind study. In Urabe H, Zaias N, Stettendorf S (eds) International antifungal symposium, Tokyo Exerpta Medica 1982, pp 74
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Saffé, F. (1986). Bifonazole in Dermatological Practice: Results of a Multicentre Study. In: Hay, R.J. (eds) Advances in Topical Antifungal Therapy. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71717-8_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-71717-8_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-17302-1
Online ISBN: 978-3-642-71717-8
eBook Packages: Springer Book Archive